Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
GlaxoSmithKline, Pfizer and Shinogi’s joint venture ViiV Healthcare said the Phase III BRIGHTE study hit 96-week endpoints in heavily treatment-experienced adults with HIV-1 infection.
SCOUT, a leading healthcare marketing agency focused on orphan drugs and specialty pharmaceuticals, formed a joint venture with Rare Expertise, a company with proprietary data-driven tools for identifying and activating people with rare disorders.
In April of 2014, GSK and Novartis announced a swap of assets, with GSK acquiring the Novartis global Vaccines business (excluding influenza vaccines) and Novartis gaining the GSK Oncology business. […]